M
M Bauer
Publications - 4
Citations - 3737
M Bauer is an academic researcher. The author has contributed to research in topics: Mastectomy & Total Mastectomy. The author has an hindex of 3, co-authored 3 publications receiving 3674 citations.
Papers
More filters
Journal ArticleDOI
Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer
Bernard Fisher,M Bauer,Richard G. Margolese,Roger Poisson,Yosef Pilch,Carol K. Redmond,Edwin R. Fisher,Norman Wolmark,Melvin Deutsch,E Montague +9 more
TL;DR: It is concluded that segmental mastectomy, followed by breast irradiation in all patients and adjuvant chemotherapy in women with positive nodes, is appropriate therapy for Stage I and II breast tumors less than or equal to 4 cm, provided that margins of resected specimens are free of tumor.
Journal ArticleDOI
Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
Bernard Fisher,Carol K. Redmond,Edwin R. Fisher,M Bauer,Norman Wolmark,Wickerham Dl,Melvin Deutsch,E Montague,Richard G. Margolese,Roger S. Foster +9 more
TL;DR: It is indicated that the location of a breast tumor does not influence the prognosis and that irradiation of internal mammary nodes in patients with inner-quadrant lesions does not improve survival and that the results obtained at five years accurately predict the outcome at 10 years.
Journal Article
The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast.
Journal ArticleDOI
Rejoinder: Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
Kelly Van Lancker,Sergey Tarima,Jonathan Bartlett,M Bauer,Bharani Bharani-Dharan,Frank Bretz,Nancy Flournoy,Hege Michiels,Camila Olarte Parra,James L. Rosenberger,Suzie Cro +10 more
TL;DR: This article demonstrates how the ICH E9(R1) Addendum on estimands and analyses provides a rigorous basis to discuss potential pandemic-related trial disruptions and to embed these disruptions in the context of study objectives and design elements.